{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-002160","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2025-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.578493+00:00","generated_at":"2026-05-27T07:08:30.401316+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NRx Pharmaceuticals secures $8.9M financing from Anson Funds to support NDA filings, operations into 2026","bullets":["Issued $5.435M senior secured notes (net proceeds ~$5M) and warrants for 862,699 shares at $3.78 strike; registered direct offering of 1,215,278 shares at $2.88/share.","Total gross proceeds of ~$8.9M from Anson Funds; notes carry 8% OID, 6% interest, 15-month maturity, convertible at $3.78/share subject to reset.","Proceeds will fund NRX-100 and NRX-101 NDA filings, HOPE Therapeutics launch, and potential pipeline additions; expected to fund operations into 2026.","Company believes combined with projected sales and non-dilutive funding it can reach profitability; includes waiver of certain investor rights through March 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-002160","json":"https://secwatch.observer/filing/0001437749-25-002160.json","markdown":"https://secwatch.observer/filing/0001437749-25-002160.md","text":"https://secwatch.observer/filing/0001437749-25-002160.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925002160/0001437749-25-002160-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925002160/nrxp20250128_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T07:08:30.401316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}